The correlation between lateral bowing angle of the femur and the location of atypical femur fractures

Calcified Tissue International

Volumn 95, Issue 3, 2014, Pages 240-247

  Chen, Lei Po ^a   Chang, Ting Kuo ^a   Huang, Te Yang ^a   Kwok, Tiew Guan ^a   Lu, Yung Chang ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Atypical femur fracture; Bisphosphonate; Femur curvature; Lateral femur bowing angle; Postmenopausal women

Indexed keywords

ALENDRONIC ACID; FOSAMAX PLUS; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; ATYPICAL FEMUR FRACTURE; BONE BOWING; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; CLINICAL ARTICLE; DIAPHYSIS; FEMALE; FEMUR CONDYLE; FEMUR FRACTURE; FEMUR SHAFT; GREATER TROCHANTER; HUMAN; LATERAL FEMUR BOWING ANGLE; MIDDLE AGED; PRIORITY JOURNAL; VERY ELDERLY; WEIGHT BEARING; FEMUR; FRAGILITY FRACTURE; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FEMUR; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84906346716     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-014-9887-y     Document Type: Article

References (36)

1. Black DM et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535-1541 (Pubitemid 26411651)
2. Harris ST et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344-1352 (Pubitemid 29483192)
3. Black DM et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809-1822
4. Body JJ (2006) Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14(5):408-418
5. Black DM et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362(19):1761-1771
6. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358(12):1304-1306 (Pubitemid 351439247)
7. Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728-1737
8. Dell RM et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544-2550
9. Meier RP et al (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930-936
10. Shane E et al (2013) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1-23
11. Capeci CM, Tejwani NC (2009) Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91(11):2556-2561
12. Goddard MS et al (2009)Atraumatic bilateral femur fracture in longterm bisphosphonate use. Orthopedics. doi:10.3928/01477447-20090624-27
13. Lee JK (2009) Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis 12(2):149-154
14. Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169-180
15. Lo JC et al (2012) Clinical correlates of atypical femoral fracture. Bone 51(1):181-184
16. Sasaki S et al (2012) Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab 30(5):561-567
17. Hsu RW et al (1990) Normal axial alignment of the lower extremity and load-bearing distribution at the knee. Clin Orthop Relat Res 255:215-227 (Pubitemid 20187451)
18. Yau WP et al (2007) Coronal bowing of the femur and tibia in Chinese: its incidence and effects on total knee arthroplasty planning. J Orthop Surg (Hong Kong) 15(1):32-36
19. Koh JS et al (2011) Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 52(2):77-80
20. Shane E et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267-2294
21. Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22(11):1759-1765 (Pubitemid 351235142)
22. Brennan O et al (2011) Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res 29(3):419-424
23. Renders GA et al (2011)Mineral heterogeneity affects predictions of intratrabecular stress and strain. J Biomech 44(3):402-407
24. Saito M et al (2008) Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19(9):1343-1354
25. Tang SY et al (2009) Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 20(6):887-894
26. Unnanuntana A et al (2013) Atypical femoral fractures: what do we know about them?: AAOS exhibit selection. J Bone Joint Surg Am 95(2):e8-e13
27. Mullaji AB, Marawar SV, Mittal V (2009) A comparison of coronal plane axial femoral relationships in Asian patients with varus osteoarthritic knees and healthy knees. J Arthroplast 24(6):861-867
28. Nagamine R et al (2000) Anatomic variations should be considered in total knee arthroplasty. J Orthop Sci 5(3):232-237 (Pubitemid 30431798)
29. Crossley K et al (1999) Ground reaction forces, bone characteristics, and tibial stress fracture in male runners. Med Sci Sports Exerc 31(8):1088-1093 (Pubitemid 29395226)
30. Roschger P et al (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29(2):185-191 (Pubitemid 32737191)
31. Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20(5):793-800
32. Donnelly E et al (2012) Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 27(3):672-678
33. Roschger P et al (2008) Bone mineralization density distribution in health and disease. Bone 42(3):456-466
34. Huang TW et al (2011) Total knee replacement in patients with significant femoral bowing in the coronal plane: a comparison of conventional and computer-assisted surgery in an Asian population. J Bone Joint Surg Br 93(3):345-350
35. Maratt J et al (2014) Variation in the femoral bow: a novel high-throughput analysis of 3922 femurs on cross-sectional imaging. J Orthop Trauma 28(1):6-9
36. Mohan PC et al (2013) Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol 23(1):222-227